Article
Hematology
Sara Butera, Marco Cerrano, Lucia Brunello, Chiara Maria Dellacasa, Danilo Giuseppe Faraci, Sara Vassallo, Nicola Mordini, Roberto Sorasio, Francesco Zallio, Alessandro Busca, Benedetto Bruno, Luisa Giaccone
Summary: The study suggests that lower doses of ATG may be beneficial in adult patients receiving allo-HCT from matched unrelated donors, leading to prolonged overall survival and disease-free survival, reduced infection-related mortality, and improved graft and relapse-free survival.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Lu Wang, Peiyan Kong, Cheng Zhang, Li Gao, Lidan Zhu, Jia Liu, Shichun Gao, Ting Chen, Huanfeng Liu, Han Yao, Yuqing Liu, Yimei Feng, Lu Zhao, Yuxia Li, Lei Gao, Xi Zhang
Summary: This study compared the outcomes of patients with hematological malignancies who received different preparations of rabbit antithymocyte globulin (ATG) in unrelated donor hematopoietic stem cell transplantation (HSCT). The results showed that the type of ATG preparation had no significant effect on various outcomes, except for a lower risk of extensive chronic graft-versus-host disease (GVHD) and a higher risk of cytomegaloviremia in patients who received ATG-Genzyme (ATG-G). The study suggests that the choice of ATG preparation should be based on the incidence of extensive chronic GVHD, and the posttransplant management strategy should be adjusted accordingly.
ANNALS OF HEMATOLOGY
(2023)
Review
Oncology
Lu Tang, Zhigang Liu, Tao Li, Tian Dong, Qiuhui Wu, Ting Niu, Ting Liu, Jie Ji
Summary: Through investigating 1091 articles, it was found that the PTCy prophylaxis regimen can reduce the incidence of aGVHD, decrease NRM and EBV-related complications, and achieve better OS compared to the ATG-based regimen. There was no significant difference between the two groups in cGVHD, RI, CMV reactivation, and BKV-related HC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Mesire Aydin, David C. C. de Leeuw, Caroline E. E. Rutten, Otto J. J. Visser, Man Wai Tang, Cinthy van Roessel, Jeroen J. W. Janssen, Bart J. J. Biemond, Arjan A. A. van de Loosdrecht, Mette D. D. Hazenberg, Ellen Meijer, Erfan Nur
Summary: A systematic comparison of transplantation outcomes between two lymphocyte-depleting strategies, ATG and PTCy, in non-myeloablative conditioning for allogeneic haematopoietic stem cell transplantation revealed a significantly lower rate of acute GvHD in the PTCy group compared to the ATG group.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Souichi Shiratori, Junichi Sugita, Shigeo Fuji, Jun Aoki, Masashi Sawa, Yukiyasu Ozawa, Daigo Hashimoto, Ken-ichi Matsuoka, Kazunori Imada, Noriko Doki, Takashi Ashida, Yasunori Ueda, Masatsugu Tanaka, Yasushi Sawayama, Tatsuo Ichinohe, Seitaro Terakura, Satoko Morishima, Yoshiko Atsuta, Takahiro Fukuda, Takanori Teshima
Summary: Low-dose ATG effectively suppresses chronic GVHD in unrelated PBSCT, and ALC before ATG may be a potential predictor for GVHD and relapse.
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Fumiya Wada, Mizuki Watanabe, Takaaki Konuma, Motohito Okabe, Shinichi Kobayashi, Naoyuki Uchida, Kazuhiro Ikegame, Masatsugu Tanaka, Yasuhiro Sugio, Junichi Mukae, Makoto Onizuka, Toshiro Kawakita, Takuro Kuriyama, Satoshi Takahashi, Takahiro Fukuda, Nobuaki Nakano, Masashi Sawa, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
Summary: This study compared the outcomes of unrelated cord blood transplantation (CBT) and HLA-mismatched related donor peripheral blood stem-cell transplantation (PBSCT) using low-dose anti-thymocyte globulin (ATG). The results showed that CBT without ATG had better overall survival, lower nonrelapse mortality, and lower severe graft-versus-host disease (GVHD) than PBSCT with low-dose ATG. However, PBSCT patients with HLA 1 antigen mismatch had similar overall survival as the CBT group.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Wenli Zhang, Ruirui Gui, Yingling Zu, Binglei Zhang, Zhen Li, Yanli Zhang, Xianjing Wang, Shuli Guo, Xinrong Zhan, Yuewen Fu, Yongping Song, Jian Zhou
Summary: This study demonstrates that the combination of reduced-dose post-transplant cyclophosphamide (PTCy) and low-dose post-transplant anti-thymocyte globulin (ATG) in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) significantly reduces the incidence of graft-versus-host disease (GVHD) and improves overall survival and disease-free survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Yingling Zu, Zhen Li, Ruirui Gui, Yanyan Liu, Yanli Zhang, Fengkuan Yu, Huifang Zhao, Yuewen Fu, Xinrong Zhan, Zhongliang Wang, Pengtao Xing, Xianjing Wang, Huili Wang, Jian Zhou, Yongping Song
Summary: This study evaluated a novel regimen for graft-versus-host disease (GVHD) prophylaxis in HLA-matched unrelated donor peripheral blood stem cell transplantation (MUD-PBSCT), which significantly reduced the incidence of acute GVHD (aGVHD) and chronic GVHD (cGVHD) by using a combination of low-dose post-transplant cyclophosphamide (PTCy) and low-dose anti-thymocyte globulin (ATG). The regimen also improved non-relapse mortality (NRM) and GVHD-free, relapse-free survival (GRFS) in patients with hematological malignancies in first remission (CR1).
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Yasushi Onishi, Takehiko Mori, Hirohito Yamazaki, Katsuto Takenaka, Hiroki Yamaguchi, Naoki Shingai, Yukiyasu Ozawa, Hiroatsu Iida, Shuichi Ota, Naoyuki Uchida, Toshihiro Miyamoto, Yuta Katayama, Jun Kato, Satoshi Yoshioka, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta
Summary: The study found that the choice between CSA + MTX or TAC + MTX did not significantly impact acute and chronic GVHD, OS, or GRFS. The use of ATG in conditioning reduced the risk of acute GVHD and improved GRFS in recipients of marrow from matched sibling donors.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Georgina Gener, Montserrat Batlle, Mireia Morgades, Maria-Jose Jimenez, Christelle Ferra, Josep-Maria Ribera
Summary: This retrospective study analyzed the outcomes and frequency of infections in patients with acute leukemia and myelodysplastic syndrome after unrelated donor stem cell transplantation with or without anti-thymocyte globulin (ATG). The results showed no significant differences in main outcomes between the ATG group and no-ATG group, but a higher frequency of infections in the ATG group.
Article
Medicine, General & Internal
Cora E. Lewis, Lawrence J. Fine, Srinivasan Beddhu, Alfred K. Cheung, William C. Cushman, Jeffrey A. Cutler, Gregory W. Evans, Karen C. Johnson, Dalane W. Kitzman, Suzanne Oparil, Mahboob Rahman, David M. Reboussin, Michael V. Rocco, Kaycee M. Sink, Joni K. Snyder, Paul K. Whelton, Jeff D. Williamson, Jackson T. Wright, Walter T. Ambrosius
Summary: Among patients at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and all-cause mortality compared to targeting a systolic blood pressure of less than 140 mm Hg, both during the trial and post-trial follow-up. However, some adverse events were more frequent in the intensive-treatment group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Oncology
Xue Yang, Dongjun Li, Yao Xie
Summary: ATG significantly reduced the incidence and severity of GVHD, improved GRFS, and reduced the number and dose of immunosuppressants in patients undergoing allo-HSCT.
FRONTIERS IN ONCOLOGY
(2021)
Article
Infectious Diseases
Anette Veringa, Roger J. Bruggemann, Lambert F. R. Span, Bart J. Biemond, Mark G. J. de Boer, Edwin R. van den Heuvel, Saskia K. Klein, Doris Kraemer, Monique C. Minnema, Niek H. J. Prakken, Bart J. A. Rijnders, Jesse J. Swen, Paul E. Verweij, Marielle J. Wondergem, Paula F. Ypma, Nicole Blijlevens, Jos G. W. Kosterink, Tjip S. van der Werf, Jan-Willem C. Alffenaar
Summary: This study investigated whether TDM-guided voriconazole treatment is superior to standard treatment for invasive aspergillosis. The results showed no significant difference in treatment outcome and adverse reactions between the TDM and non-TDM groups, but a higher proportion of voriconazole concentrations within the acceptable range were found in the TDM group.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Biophysics
Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatiana Zabelina, Christine Wolschke, Francis Ayuk, Ulrike Fritzsche-Friedland, Axel Zander, Nicolaus Kroeger
Summary: This study compared the impact of different doses of Anti-lymphocyte globulin on transplantation outcomes. Higher doses were associated with delayed engraftment and increased infection risks, while lower doses facilitated faster immune reconstitution.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Carla Minoia, Lucia Diella, Tommasina Perrone, Giacomo Loseto, Carmen Pelligrino, Immacolata Attolico, Crescenza Pasciolla, Valentina Totaro, Maria Stella De Candia, Vito Spada, Felice Clemente, Michele Camporeale, Francesco Di Gennaro, Attilio Guarini, Pellegrino Musto, Annalisa Saracino, Davide Fiore Bavaro
Summary: High rates of lung failure have been observed in haematological patients with SARS-CoV2 infection. Early administration of monoclonal antibodies or antivirals may improve prognosis. The use of oral antivirals may have broader applications regardless of the genetic variations of the virus.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biophysics
Basil Sharrack, Riccardo Saccardi, Tobias Alexander, Manuela Badoglio, Joachim Burman, Dominique Farge, Raffaella Greco, Helen Jessop, Majid Kazmi, Kirill Kirgizov, Myriam Labopin, Gianluigi Mancardi, Roland Martin, John Moore, Paolo A. Muraro, Montserrat Rovira, Maria Pia Sormani, John A. Snowden, John Snowden, Eoin McGrath, Franco Bambi, Fermin Sanchez-Guijo, Nina Worel, Manuela Badolglio, Mario Abinun, Renate Arnold, Charlotte Brierley, Cristina Castilla-Llorente, Nichola Cooper, Thomas Daikeler, Nicoletta del Papa, Jurgen Finke, Hans Hagglund, Joerg Henes, Falk Hiepe, David Kiely, Zora Marjanovic, Thierry Martin, David Ma, Paul Miller, Paolo Muraro, Maria-Carolina Oliveira, Alexey Polushin, Francesco Onida, Belinda Simoes, Mathieu Puyade, Igor Resnick, Muhammad Saif, Ioanna Sakellari, Emilian Snarski, Hans Ulrich Scherer, Claudia Sossa, Jeska de Vries-Bouwstra, Nico Wulffraat, Eleanora Zaccara
BONE MARROW TRANSPLANTATION
(2020)
Correction
Biophysics
John A. Snowden, Riccardo Saccardi, Kim Orchard, Per Ljungman, Rafael F. Duarte, Myriam Labopin, Eoin McGrath, Nigel Brook, Carmen Ruiz de Elvira, Debra Gordon, Helene A. Poirel, Francis Ayuk, Yves Beguin, Francesca Bonifazi, Alois Gratwohl, Noel Milpied, John Moore, Jakob Passweg, J. Douglas Rizzo, Stephen R. Spellman, Jorge Sierra, Carlos Solano, Fermin Sanchez-Guijo, Nina Worel, Andreu Gusi, Gillian Adams, Theodor Balan, Helen Baldomero, Gilles Macq, Evelyne Marry, Florence Mesnil, Elena Oldani, Rachel Pearce, Julia Perry, Nicole Raus, Urs Schanz, Steven Tran, Leonie Wilcox, Grzegorz W. Basak, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Jurgen Kuball, Mohamad Mohty, Arjan Lankester, Sylvia Montoto, Arnon Nagler, Jan Styczynski, Ibrahim Yakoub-Agha, Regis Peffault de Latour, Nicolaus Kroeger, Ronald Brand, Liesbeth C. de Wreede, Erik van Zwet, Hein Putter
BONE MARROW TRANSPLANTATION
(2020)
Article
Hematology
Sandra Cohen, Jean Roy, Silvy Lachance, Jean-Sebastien Delisle, Anne Marinier, Lambert Busque, Denis-Claude Roy, Frederic Barabe, Imran Ahmad, Nadia Bambace, Lea Bernard, Thomas Kiss, Philippe Bouchard, Pierre Caudrelier, Severine Landais, Fannie Larochelle, Jalila Chagraoui, Bernhard Lehnertz, Sophie Corneau, Elisa Tomellini, Jeroen J. A. van Kampen, Jan J. Cornelissen, Maude Dumont-Lagace, Megane Tanguay, Qi Li, Sebastien Lemieux, Peter W. Zandstra, Guy Sauvageau
LANCET HAEMATOLOGY
(2020)
Review
Biophysics
M. Newmarch, E. Kostantin, G. J. Tsongalis, M. Guimond, J. Roy, V. De Guire, I. Ahmad
BONE MARROW TRANSPLANTATION
(2020)
Letter
Biophysics
Georgia McCaughan, David Ma, John Moore
BONE MARROW TRANSPLANTATION
(2021)
Article
Hematology
Jean-Sebastien Claveau, Sandra Cohen, Imran Ahmad, Thomas Kiss, Silvy Lachance, Guy Sauvageau, Lambert Busque, Nadia Bambace, Lea Bernard, Denis Claude Roy, Jean Roy
EUROPEAN JOURNAL OF HAEMATOLOGY
(2020)
Article
Hematology
Maude Dumont-Lagace, Qi Li, Megane Tanguay, Jalila Chagraoui, Tibila Kientega, Guillaume B. Cardin, Ann Brasey, Assya Trofimov, Cedric Carli, Imran Ahmad, Nadia M. Bambace, Lea Bernard, Thomas L. Kiss, Jean Roy, Denis-Claude Roy, Sebastien Lemieux, Claude Perreault, Francis Rodier, Simon Frederic Dufresne, Lambert Busque, Silvy Lachance, Guy Sauvageau, Sandra Cohen, Jean-Sebastien Delisle
Summary: UM171-expanded cord blood transplantation allows for rapid T cell reconstitution and increased T cell diversity, resulting in lower rates of infection and reduced incidence of chronic graft-versus-host disease and transplant-related mortality.
TRANSPLANTATION AND CELLULAR THERAPY
(2021)
Article
Surgery
Richard LeBlanc, Jean-Sebastien Claveau, Imran Ahmad, Jean-Sebastien Delisle, Nadia Bambace, Lea Bernard, Sandra Cohen, Thomas Kiss, Silvy Lachance, Severine Landais, Denis Claude Roy, Guy Sauvageau, Jean Roy
CLINICAL TRANSPLANTATION
(2020)
Article
Biophysics
Richard LeBlanc, Imran Ahmad, Rafik Terra, Jean-Samuel Boudreault, David Ogez, Kristopher Lamore, Jean-Sebastien Delisle, Nadia Bambace, Lea Bernard, Sandra Cohen, Thomas Kiss, Silvy Lachance, Severine Landais, Emilie Lemieux-Blanchard, Guy Sauvageau, Michael Sebag, Denis Claude Roy, Jean Roy
Summary: Despite novel drugs and autologous HCT, MM remains incurable and patients with poor biological characteristics have short survival. Allo HCT may cure some patients but is hindered by high toxicity and relapse. BTZ may improve PFS and cGVHD after allo HCT in newly diagnosed MM patients, with promising results in this prospective phase II study.
BONE MARROW TRANSPLANTATION
(2022)
Letter
Oncology
Jean-Sebastien Claveau, Sophie Savary Belanger, Imran Ahmad, Jean-Sebastien Delisle, Vincent De Guire, Jean Roy, Richard LeBlanc
BLOOD CANCER JOURNAL
(2022)
Article
Hematology
Sylvie Lachance, Alex Bourguignon, Josie-Anne Boisjoly, Philippe Bouchard, Imran Ahmad, Nadia Bambace, Lea Bernard, Sandra Cohen, Jean-Sebastien Delisle, Isabelle Fleury, Thomas Kiss, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux, Justine Zehr, Miguel Chagnon, Jean Roy
Summary: With the emergence of new cellular and targeted therapies, there are now more treatment options for relapsed and refractory lymphomas. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered a viable treatment option for chemosensitive lymphomas. Carmustine (BCNU)-based preparative regimens, such as BEAM and BEAC, are the established standard of care. A study compared the substitution of BCNU with bendamustine (benda) in the preparative regimen and found that benda-EAM conditioning showed better outcomes in terms of survival rates.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Oncology
Yasmine Kadri, Michelle Phan, Nadia Bambace, Lea Bernard, Sandra Cohen, Jean-Sebastien Delisle, Thomas Kiss, Sylvie Lachance, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux, Jean Roy, Imran Ahmad
Summary: The study investigated the correlation between donor age and non-relapse mortality and relapse incidence in patients receiving allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. The results showed that donor age was associated with non-relapse mortality but not relapse incidence. Donors over the age of 50 had a greater impact on non-relapse mortality. Additionally, donor age was associated with the occurrence of chronic graft-versus-host disease.
Article
Hematology
Olivier Veilleux, Jean-Sebastien Claveau, Habiba Alaoui, Jean Roy, Imran Ahmad, Jean-Sebastien Delisle, Thomas Kiss, Nadia M. Bambace, Lea Bernard, Sandra Cohen, Guy Sauvageau, Isabelle Fleury, Luigina Mollica, Denis-Claude Roy, Yasmina Serroukh, Sylvie Lachance
Summary: This study retrospectively analyzed the outcomes of 89 consecutive patients with relapsed/refractory Hodgkin lymphoma who underwent autologous hematopoietic stem cell transplantation (autoHSCT). With a median follow-up of 5 years, the estimated 5-year progression-free survival (PFS) and overall survival (OS) rates for patients undergoing autoHSCT were 57.5% and 81.3%, respectively. Corresponding values for patients who underwent allogeneic HSCT (alloHSCT) were 76.5% and 82.4%. Both autoHSCT and alloHSCT provide robust and prolonged disease control.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Correction
Oncology
S. Thiant, M. M. Moutuou, P. Laflamme, R. Sidi Boumedine, D. M. Leboeuf, L. Busque, J. Roy, M. Guimond
BLOOD CANCER JOURNAL
(2020)